GlassScriptPhysician profile
Heather L Mckenzie
NPI 1053335059
$950.98
in general payments reported to CMS, 2019-2025
16 companies · $36.76 in 2025
The $36.76 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $303 · 2021: $102 · 2022: $84.91 · 2023: $150 · 2024: $47.15 · 2025: $36.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $233.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $230.96 | 2020-2022 | |
| Abbvie INC. | $222.12 | 2021-2024 | |
| Supernus Pharmaceuticals, INC. | $158.01 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $76.04 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $51.61 | 2019-2020 | |
| Amarin Pharma, INC. | $39.27 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $33.36 | 2020 | |
| Novartis Pharmaceuticals Corporation | $23.62 | 2019 | |
| Galderma Laboratories, L.P. | $21.87 | 2025 | |
| Abbott Laboratories | $16.97 | 2020 | |
| Revance Therapeutics, INC. | $14.89 | 2025 | Daxxify |
| Adlon Therapeutics L.P. | $13.73 | 2020 | |
| Amgen INC. | $13.23 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.53 | 2021 | |
| Orexo US, INC. | $11.44 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Misonix INC | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Mckenzie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.